Main Line Health

DocGo Announces Record Third Quarter 2023 Results

Retrieved on: 
Monday, November 6, 2023
Telemedicine, Virtual Medicine, Internet, Health, Hospitals, Health Technology, Technology, Mobile, Wireless, Other Health, Partner, Children's Acute Transport Service, South Central Ambulance Service, New York City Department of Housing Preservation and Development, HPD, EBITDA, Transport, Workforce, GAAP, Quality of life, MHealth, Cancer, Growth, RFP, Partnership, Housing, Great Places, EmblemHealth, Patient, Main Line Health, Uncertainty, Treasurer, Video game, Beauty salon, Management, Hospital, Pharmaceutical industry, Bookkeeping

Gross margin for the third quarter of 2023 was 29.5%, compared to 33.4% in the second quarter of 2023 and 31.7% in the third quarter of 2022.

Key Points: 
  • Gross margin for the third quarter of 2023 was 29.5%, compared to 33.4% in the second quarter of 2023 and 31.7% in the third quarter of 2022.
  • Net income margin was 2.5% for the third quarter of 2023, compared to 1.0% in the second quarter of 2023 and 2.4% in the third quarter of 2022.
  • Adjusted EBITDA2 was $16.7 million for the third quarter of 2023, up 84% from $9.1 million in the second quarter of 2023 and up 99% from $8.4 million in the third quarter of 2022.
  • Adjusted EBITDA margin2 for the third quarter of 2023 was 9.0%, compared to 7.3% in the second quarter of 2023 and 8.1% in the third quarter of 2022.

Conformal Medical Announces Compelling One-Year Data from its Left Atrial Appendage Occlusion (LAAO) Early Feasibility Study

Retrieved on: 
Tuesday, October 24, 2023
Stroke, Atrial fibrillation, Ventricular fibrillation, Structure, Physician, Conformal, CLAAS, TEE, Anticoagulant, LAA, Risk, EFS, Safety, TCT, Patient, Main Line Health, Thomas Jefferson University, Medical device, Medicine

CLAAS® System live case presentation by Dr. Shephal Doshi on Thursday, October 26th

Key Points: 
  • CLAAS® System live case presentation by Dr. Shephal Doshi on Thursday, October 26th
    NASHUA, N.H., Oct. 24, 2023 /PRNewswire/ -- Conformal Medical, Inc. announced today the positive one-year results from the company's CONFORMAL Early Feasibility Study (EFS).
  • "These results are clinically compelling and support the feasibility of the CLAAS System to safely and effectively provide durable closure for LAAO indicated patients."
  • The multi-center, single-arm, prospective study enrolled patients indicated for LAAO at 10 U.S. clinical sites.
  • Wednesday, October 25th - Conformal Medical to host a breakfast symposium, "CLAAS Act: Conformal Medical Overview and CONFORM Trial Update" at 6:30am PT in Presentation Theater 1.

Conformal Medical to Present One-Year Data from its Left Atrial Appendage Occlusion (LAAO) Early Feasibility Study at TCT 2023

Retrieved on: 
Thursday, October 19, 2023
Stroke, Medical research, Atrial fibrillation, Ventricular fibrillation, Lankenau Institute for Medical Research, Structure, Conformal, Health, CLAAS, TEE, Anticoagulant, LAA, Risk, EFS, Safety, TCT, Patient, Main Line Health, Medical device

NASHUA, N.H., Oct. 19, 2023 /PRNewswire/ -- Conformal Medical, Inc. announced today the one-year results from the company's CONFORMAL Early Feasibility Study (EFS) will be presented during the 2023 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, CA. Dr. William Gray, System Chief, Cardiovascular Diseases at Main Line Health and professor at Lankenau Institute for Medical Research will present, "Conformal CLAAS LAAO Device EFS 1-Year TEE Follow Up" during a moderated abstract session.

Key Points: 
  • "I look forward to presenting the much anticipated one-year TEE follow up data from our initial clinical experience," stated Dr. Gray.
  • "We are extremely pleased to have the one-year Conformal EFS data presented at this year's TCT conference," commented James Reinstein, CEO of Conformal Medical.
  • Conformal Medical is currently enrolling patients in its CONFORM Pivotal Trial to support U.S. commercialization.
  • Wednesday, October 25th - Conformal Medical to host a breakfast symposium, "CLAAS Act: Conformal Medical Overview and CONFORM Trial Update" at 6:30am PT in Presentation Theater 1.

DocGo Partners with Main Line Health in Philadelphia to Provide Medical Transportation, and Agrees to Collaborate on Remote Patient Monitoring Initiatives

Retrieved on: 
Wednesday, October 4, 2023
Software, Telemedicine, Virtual Medicine, Internet, Health, Other Transport, Health Technology, Technology, Transport, Main Line Health, Asthma, Diabetes, Lankenau Medical Center, Health status of Asian Americans, Quality of life, Ambulance, Hypertension, Hospital, Patient, Physician, Bryn Mawr Hospital, Paoli Hospital, RPM

DocGo Inc. (Nasdaq:DCGO), a leading provider of technology-enabled mobile health services, announced today that its Ambulnz subsidiary will provide medical transportation service to Main Line Heath’s five-hospital health system in the greater Philadelphia area.

Key Points: 
  • DocGo Inc. (Nasdaq:DCGO), a leading provider of technology-enabled mobile health services, announced today that its Ambulnz subsidiary will provide medical transportation service to Main Line Heath’s five-hospital health system in the greater Philadelphia area.
  • The three-year medical transportation contract solidifies Ambulnz’s position as one of the largest medical transportation providers in the Philadelphia metro area.
  • Ambulnz estimates that it will provide transportation to more than 12,000 Main Line Health patients annually as part of this contract.
  • “Remote patient monitoring extends the reach of our hospital partners beyond their facilities to connect with patients where they live.

One Call Names Howard Cutler Chief Strategy & Network Officer

Retrieved on: 
Tuesday, October 3, 2023
Medicare Advantage, University, Aetna, Temple University, Marketing, Culture, Main Line Health, Universal Health Services, MBA, Horizon Blue Cross Blue Shield of New Jersey, Strategic planning, Cutler, Howard Cutler, Organization, Medicare, ACA, Coventry Health Care, UHS, NYSE, Management, Health insurance

JACKSONVILLE, Fla., Oct. 3, 2023 /PRNewswire-PRWeb/ -- One Call, a care coordination leader within the workers' compensation industry, today announced that Howard Cutler – a highly accomplished healthcare executive – has been named the organization's chief strategy and network officer (CSNO). 

Key Points: 
  • JACKSONVILLE, Fla., Oct. 3, 2023 /PRNewswire-PRWeb/ -- One Call, a care coordination leader within the workers' compensation industry, today announced that Howard Cutler – a highly accomplished healthcare executive – has been named the organization's chief strategy and network officer (CSNO).
  • The newly created role brings together two key business functions – corporate strategy and network management and development – to further advance the organization.
  • As a member of One Call's executive committee, Cutler will be responsible for leading strategic planning efforts and driving the execution of key initiatives.
  • He will oversee the organization's provider network, product management, and marketing teams, effectively leveraging all three areas to better serve clients and injured workers.

Philadelphia-area health organizations form Regional Coalition to Eliminate Race-Based Medicine

Retrieved on: 
Thursday, August 10, 2023
Children's Hospital of Philadelphia, Independence Blue Cross, Trinity Health Mid-Atlantic, IBC, Pediatrics, Temple University Hospital, Temple University, St. Christopher's Hospital for Children, Main Line Health, Hospital, Nemours Children's Hospital, Delaware, Health equity, Health, Saint Christopher, Senior, Virtua Health, FAAP, Comfort, Regional Coalition for Clean Rivers and Streams, Jefferson Health, Population health, Patient, Protocol, Heal, JD, Inclusion, Racism, Region, MPH, Trinity Health, Disease, Vaccine, Nursing, Independence, Women & Health, Child, Doctor of Philosophy, MD, Medicine

Jefferson Health is proud to be a part of the Regional Coalition to Eliminate Race-Based Medicine in our effort to eliminate race as a factor in our clinical decision-making tools," said Dwight W. McBee, executive vice president and chief experience officer at Jefferson Health.

Key Points: 
  • Jefferson Health is proud to be a part of the Regional Coalition to Eliminate Race-Based Medicine in our effort to eliminate race as a factor in our clinical decision-making tools," said Dwight W. McBee, executive vice president and chief experience officer at Jefferson Health.
  • "As a leading multi-state children's health system, Nemours Children's Health is well-poised to act as a force-multiplier for health equity.
  • "With our continued focus on delivering safe, high-quality, and equitable care, Main Line Health is proud to join the Regional Coalition to Eliminate Race-Based Medicine.
  • The coalition brings together the region's leading health care organizations to address longstanding racial inequities in how medical decisions are made.

Main Line Health honored with American Hospital Association's prestigious Quest for Quality Prize

Retrieved on: 
Thursday, July 13, 2023
American Hospital Association, University, Culture, Main Line Health, Health equity, Lankenau Medical Center, Multimedia, Today, Quality, AHA, Patient safety, Bryn Mawr Hospital, Merit, System, Paoli Hospital, Knowledge, Atlantic Health System, Health, Shenzhen International BT Leadership Summit, Safety, Nursing

BRYN MAWR, Pa., July 13, 2023 /PRNewswire/ -- The American Hospital Association (AHA) today announced that Main Line Health, which serves Philadelphia and its suburbs, has been named the 2023 recipient of the American Hospital Association Quest for Quality Prize.

Key Points: 
  • BRYN MAWR, Pa., July 13, 2023 /PRNewswire/ -- The American Hospital Association (AHA) today announced that Main Line Health , which serves Philadelphia and its suburbs, has been named the 2023 recipient of the American Hospital Association Quest for Quality Prize.
  • The AHA Quest for Quality Prize is presented annually to recognize exceptional health care leadership and innovation in improving quality and advancing health in America's communities.
  • Main Line Health comprises four of the region's most respected acute care hospitals – Lankenau Medical Center , Bryn Mawr Hospital , Paoli Hospital and Riddle Hospital – as well as one of the nation's premier facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital .
  • The AHA found the leadership team members at Main Line Health demonstrate engagement and a depth of knowledge about achieving quality goals.

Luma Health Debuts Digital Call Deflection to Reduce Hold Times, Inbound Calls with Self-Service SMS

Retrieved on: 
Tuesday, June 13, 2023
Main Line Health, FQHC, Health, Patient, SAN, Mobile, DEXA, SMS, Nursing, Online shopping

SAN FRANCISCO, June 13, 2023 /PRNewswire/ -- Luma Health has launched a new Digital Call Deflection service to create a better experience for patients and reduce inbound call volume for staff by redirecting calls to self-service SMS. Luma Digital Call Deflection, now available to all health systems and clinics, helps short-staffed healthcare providers get patients to the next step in their care with a fast, easy, and customized self-service experience.

Key Points: 
  • At GPW Health Center, a federally qualified health center in Virginia, more than 25 percent of patients opted for SMS.
  • Across early adopters, Digital Call Deflection has eliminated more than 5,000 inbound calls for call center staff to handle.
  • At Main Line Health, a regional health system that integrated Luma with Epic, Digital Call Deflection has saved more than 15,000 minutes of call center time, to date.
  • At GPW Health Center, a federally qualified health center (FQHC) integrating Luma with eClinicalWorks, more than 25 percent of patients switched to SMS rather than wait on hold.

Virtual Incision Announces MIRA’s Clinical Trial Results Will Be Presented at the 2023 ASCRS Scientific Meeting

Retrieved on: 
Wednesday, May 31, 2023
Technology, FDA, Health, Robotics, Health Technology, Medical Devices, Research, Surgery, Science, Hardware, Clinical Trials, Investigational device exemption, Surgeon, De novo, Marketing, Main Line Health, Clinical trial, Lankenau Medical Center, ASCRS, Lankenau Institute for Medical Research, American Society of Colon and Rectal Surgeons, Colorectal surgery, Hospital, RAS, MIRA, IDE, Society, Medical research, Safety, Dentistry

Virtual Incision Corporation , the developer of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced that the data from its Investigational Device Exemption (IDE) clinical trial will be presented at the 2023 American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting in Seattle, WA.

Key Points: 
  • Virtual Incision Corporation , the developer of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced that the data from its Investigational Device Exemption (IDE) clinical trial will be presented at the 2023 American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting in Seattle, WA.
  • The study was designed to evaluate the safety and efficacy of MIRA for use in bowel resection procedures.
  • John Marks will unveil the full patient data set to his peer group for the very first time,” said John Murphy, president and chief executive officer of Virtual Incision.
  • Virtual Incision is the first RAS developer to complete a U.S. IDE study to support a De Novo request in bowel resection.

Vivasure Medical Announces Enrollment of First Patients in Pivotal PATCH Study

Retrieved on: 
Tuesday, May 2, 2023
Cardiology, Biotechnology, Health, General Health, Pharmaceutical, Health Technology, Medical Devices, Research, Hospitals, Science, Clinical Trials, Kaleida Health, University, University at Buffalo Law School, Stenosis, Main Line Health, Cardiovascular disease, Trial of the century, CAD, TEVAR, Patient, TAVR, Hospital, EVAR, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Aortic stenosis, Food, Safety, Pharmaceutical industry, Medical device, Buffalo

Vivasure Medical® , a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced it has enrolled the first patients in the company’s PerQseal® PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and efficacy of the Vivasure PerQseal Closure Device System.

Key Points: 
  • Vivasure Medical® , a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced it has enrolled the first patients in the company’s PerQseal® PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and efficacy of the Vivasure PerQseal Closure Device System.
  • The current approach to large-diameter arterial closure is a surgical repair or the use of suture- or collagen-based closure devices.
  • “I’m honored to participate in this study and look forward to gathering additional clinical evidence supporting this innovation’s potential benefits.”
    Vivasure’s pivotal study will enroll up to 171 patients across the U.S. and up to 90 patients in up to eight European investigational sites.
  • The data will support a pre-market approval submission to the U.S. Food and Drug Administration (FDA).